Protalix BioTherapeutics (PLX) Competitors

$2.04 +0.03 (+1.44%)

Closing price 03:59 PM Eastern

Extended Trading

$2.03 -0.01 (-0.64%)

As of 04:04 PM Eastern

PLX vs. ACRS, GYRE, CRMD, CTMX, and TLRY

Should you buy Protalix BioTherapeutics stock or one of its competitors? MarketBeat compares Protalix BioTherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protalix BioTherapeutics include Aclaris Therapeutics (ACRS), Gyre Therapeutics (GYRE), CorMedix (CRMD), CytomX Therapeutics (CTMX), and Tilray Brands (TLRY). These companies are all part of the "pharmaceutical products" industry.

How does Protalix BioTherapeutics compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Aclaris Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market.

In the previous week, Protalix BioTherapeutics had 8 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 10 mentions for Protalix BioTherapeutics and 2 mentions for Aclaris Therapeutics. Protalix BioTherapeutics' average media sentiment score of 0.55 beat Aclaris Therapeutics' score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protalix BioTherapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	80.98	-$64.92M	-$0.56	N/A
Protalix BioTherapeutics	$76.38M	2.15	$8.31M	$0.18	11.33

Aclaris Therapeutics presently has a consensus price target of $11.29, suggesting a potential upside of 148.58%. Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 488.52%. Given Protalix BioTherapeutics' higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 5.6% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Protalix BioTherapeutics has a net margin of -21.03% compared to Aclaris Therapeutics' net margin of -832.58%. Protalix BioTherapeutics' return on equity of -30.89% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Summary

Protalix BioTherapeutics beats Aclaris Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Gyre Therapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Gyre Therapeutics has a net margin of -5.44% compared to Protalix BioTherapeutics' net margin of -21.03%. Gyre Therapeutics' return on equity of 3.13% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Gyre Therapeutics	-5.44%	3.13%	2.67%

In the previous week, Protalix BioTherapeutics had 7 more articles in the media than Gyre Therapeutics. MarketBeat recorded 10 mentions for Protalix BioTherapeutics and 3 mentions for Gyre Therapeutics. Protalix BioTherapeutics' average media sentiment score of 0.55 beat Gyre Therapeutics' score of -0.32 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 10.0% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 488.52%. Gyre Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 175.88%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Protalix BioTherapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market.

Protalix BioTherapeutics has higher earnings, but lower revenue than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.15	$8.31M	$0.18	11.33
Gyre Therapeutics	$116.59M	5.13	$5.03M	-$0.09	N/A

Summary

Gyre Therapeutics beats Protalix BioTherapeutics on 9 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

CorMedix has higher revenue and earnings than Protalix BioTherapeutics. CorMedix is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.03	$163.05M	$2.13	3.78
Protalix BioTherapeutics	$76.38M	2.15	$8.31M	$0.18	11.33

CorMedix has a net margin of 45.25% compared to Protalix BioTherapeutics' net margin of -21.03%. CorMedix's return on equity of 45.57% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

CorMedix presently has a consensus target price of $15.00, indicating a potential upside of 86.22%. Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 488.52%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

34.2% of CorMedix shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, CorMedix had 6 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 16 mentions for CorMedix and 10 mentions for Protalix BioTherapeutics. CorMedix's average media sentiment score of 0.82 beat Protalix BioTherapeutics' score of 0.55 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

Summary

CorMedix beats Protalix BioTherapeutics on 12 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to CytomX Therapeutics?

Protalix BioTherapeutics (NYSE:PLX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 488.52%. CytomX Therapeutics has a consensus price target of $12.10, suggesting a potential upside of 222.24%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Protalix BioTherapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Protalix BioTherapeutics has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.15	$8.31M	$0.18	11.33
CytomX Therapeutics	$76.20M	8.39	-$17.37M	-$0.41	N/A

Protalix BioTherapeutics has a net margin of -21.03% compared to CytomX Therapeutics' net margin of -166.40%. Protalix BioTherapeutics' return on equity of -30.89% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

In the previous week, Protalix BioTherapeutics had 7 more articles in the media than CytomX Therapeutics. MarketBeat recorded 10 mentions for Protalix BioTherapeutics and 3 mentions for CytomX Therapeutics. Protalix BioTherapeutics' average media sentiment score of 0.55 beat CytomX Therapeutics' score of 0.50 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protalix BioTherapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

Summary

Protalix BioTherapeutics beats CytomX Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Tilray Brands?

Protalix BioTherapeutics (NYSE:PLX) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Protalix BioTherapeutics has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.15	$8.31M	$0.18	11.33
Tilray Brands	$821.31M	0.78	-$2.19B	-$13.65	N/A

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 488.52%. Tilray Brands has a consensus price target of $11.50, suggesting a potential upside of 110.43%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Protalix BioTherapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Protalix BioTherapeutics has a net margin of -21.03% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Tilray Brands	-156.51%	-3.31%	-2.42%

In the previous week, Protalix BioTherapeutics had 5 more articles in the media than Tilray Brands. MarketBeat recorded 10 mentions for Protalix BioTherapeutics and 5 mentions for Tilray Brands. Protalix BioTherapeutics' average media sentiment score of 0.55 beat Tilray Brands' score of 0.41 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tilray Brands	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 0.8% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Protalix BioTherapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market.

Summary

Protalix BioTherapeutics beats Tilray Brands on 10 of the 16 factors compared between the two stocks.

Get Protalix BioTherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLX vs. The Competition

Export

Metric	Protalix BioTherapeutics	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$164.29M	$308.94M	$6.34B	$23.02B
Dividend Yield	N/A	N/A	2.80%	4.13%
P/E Ratio	-15.68	N/A	20.92	30.09
Price / Sales	2.15	187.75	521.15	91.39
Price / Cash	17.80	22.44	43.18	24.44
Price / Book	4.34	4.74	9.98	4.70
Net Income	$8.31M	-$132.96M	$3.55B	$1.07B
7 Day Performance	1.95%	-0.21%	0.40%	0.11%
1 Month Performance	-8.15%	28.31%	-0.04%	0.20%
1 Year Performance	19.24%	65.57%	34.95%	28.01%

Protalix BioTherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLX Protalix BioTherapeutics	3.2419 of 5 stars	$2.04 +1.4%	$12.00 +488.5%	+16.9%	$164.29M	$76.38M	N/A	200	Analyst Revision
ACRS Aclaris Therapeutics	2.2245 of 5 stars	$4.44 +0.8%	$11.29 +154.5%	+235.6%	$620.79M	$7.83M	N/A	100
GYRE Gyre Therapeutics	2.3194 of 5 stars	$6.34 -1.6%	$17.00 +168.2%	-47.0%	$614.69M	$116.59M	N/A	40
CRMD CorMedix	3.3231 of 5 stars	$7.84 -0.9%	$15.00 +91.4%	-38.1%	$613.02M	$400.05M	3.67	30	Earnings Report Analyst Revision
CTMX CytomX Therapeutics	3.0481 of 5 stars	$3.59 +2.4%	$12.10 +237.5%	+80.6%	$608.43M	$76.20M	N/A	170	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PLX) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protalix BioTherapeutics (PLX) Competitors

PLX vs. ACRS, GYRE, CRMD, CTMX, and TLRY

How does Protalix BioTherapeutics compare to Aclaris Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Gyre Therapeutics?

Summary

How does Protalix BioTherapeutics compare to CorMedix?

Summary

How does Protalix BioTherapeutics compare to CytomX Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protalix BioTherapeutics (PLX) Competitors

PLX vs. ACRS, GYRE, CRMD, CTMX, and TLRY

How does Protalix BioTherapeutics compare to Aclaris Therapeutics?

Which has more risk & volatility, ACRS or PLX?

Does the media refer more to ACRS or PLX?

Which has better earnings and valuation, ACRS or PLX?

Do analysts prefer ACRS or PLX?

Do insiders & institutionals hold more shares of ACRS or PLX?

Is ACRS or PLX more profitable?

Summary

How does Protalix BioTherapeutics compare to Gyre Therapeutics?

Is PLX or GYRE more profitable?

Does the media prefer PLX or GYRE?

Do insiders and institutionals hold more shares of PLX or GYRE?

Do analysts prefer PLX or GYRE?

Which has more risk and volatility, PLX or GYRE?

Which has better earnings and valuation, PLX or GYRE?

Summary

How does Protalix BioTherapeutics compare to CorMedix?

Which has better valuation and earnings, CRMD or PLX?

Is CRMD or PLX more profitable?

Do analysts recommend CRMD or PLX?

Do institutionals and insiders believe in CRMD or PLX?

Does the media favor CRMD or PLX?

Which has more risk and volatility, CRMD or PLX?

Summary

How does Protalix BioTherapeutics compare to CytomX Therapeutics?

Do analysts rate PLX or CTMX?

Do institutionals & insiders believe in PLX or CTMX?

Which has better earnings and valuation, PLX or CTMX?

Is PLX or CTMX more profitable?

Does the media prefer PLX or CTMX?

Which has more risk and volatility, PLX or CTMX?

Summary

How does Protalix BioTherapeutics compare to Tilray Brands?

Which has higher valuation and earnings, PLX or TLRY?

Do analysts rate PLX or TLRY?

Is PLX or TLRY more profitable?

Does the media prefer PLX or TLRY?

Do insiders and institutionals hold more shares of PLX or TLRY?

Which has more risk and volatility, PLX or TLRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools